Complete synthetic genes with 100% sequence verification are provided in a plasmid cloning vector and ready to use in a variety of applications.
* Gene sequences with added complexity can interfere with assembly and/or sequencing performance. Such sequences may result in less synthesis yield and/or additional services charges.
1 The time required to manufacture a gene is dependent on length, complexity, and vector choice. >85% orders are ready to ship within the number of business days indicated. Sequences that are unstable and/or toxic to E. coli can substantially affect delivery times.
Sequence Information is secure and confidential at IDT. Please see our Confidentiality Statement for more information.
All Genes and MiniGene™ Synthetic Genes are constructed with either gBlocks® Gene Fragments or Ultramer® DNA Oligos, and are sequence verified by either Sanger or MiSeq™ system. The exact method used will be determined by IDT as part of the manufacturing process. Your custom genes will arrive dry in a plasmid cloning vector, ready to be used in a variety of applications.
Under Ordering, click on the Order now button and select the Bulk Input option at the top left of the ordering tool. Separate your sequences by name as you import Excel or text files.
Your order request will be reviewed for the following characteristics which may interfere with synthesis, assembly, or sequencing performance. Potential issues include:
If the sequence does not pass the screening criteria, you will be contacted by a gene services specialist to determine the best way to proceed.
All of our synthetic gene products are provided in an optimized cloning vector that is ready to be transformed into E. coli. To optimize manufacturing and delivery times, synthetic genes ≤5 kb in length are delivered in a “best-fit” vector (Table 1), for which you can choose between ampicillin or kanamycin selection markers. Upon receiving your gene, you can then subclone it into the vector of your choice using a variety of methods. The identity of the cloning vector used, its sequence, and insertion site will be confirmed in the documentation that accompanies your product.
|Vector name||Vector size||Selection marker||Application||Sequence|
|pUCIDT (Amp)||2752||Ampicillin||Cloning||pUCIDT (Amp).txt|
|pUCIDT (Amp) Golden Gate||2752||Ampicillin||Cloning||pUCIDT (Amp) Golden Gate.txt|
|pUCIDT (Kan)||2705||Kanamycin||Cloning||pUCIDT (Kan).txt|
|pIDTSmart (Amp)||2056||Ampicillin||Cloning||pIDTSmart (Amp).txt|
|pIDTSmart (Kan)||1962||Kanamycin||Cloning||pIDTSmart (Kan).txt|
All inserts for Genes and MiniGene products are sequence verified on both strands. For genes ≤5000 bp, Sanger sequencing information, including chromatograms, a plasmid map, and a FASTA file are available to you via your online IDT account. In some cases, Sanger sequencing may be substituted with MiSeq® system (Illumina) data.
A sequencing certificate of analysis will be provided for genes ≥5001 bp. To download your sequence information, log in to your account, click on the Order Menu tab, and click the View All link next to Order History in Your Order Center, on the right-hand side of the page. Locate your order number in the order history and click on the QC link within your order to download the supporting files for your gene.
All sequence information is always secure and confidential at IDT. Non-disclosure agreements are available through our legal services upon request.
We screen the sequence of every gene order we receive to (1) identify any regulated and other potentially dangerous pathogen sequences, and (2) verify that IDT’s gene customers are legitimate scientists engaged in beneficial research.
IDT is among the five founding members of the International Gene Synthesis Consortium (IGSC), and helped to create the IGSC’s Harmonized Screening Protocol. The Harmonized Screening Protocol describes the gene sequence and customer screening practices that IGSC member companies employ to prevent the misuse of synthetic genes. IDT takes the steps set out in the Harmonized Screening Protocol to screen the sequences of ordered genes and the prospective customers who submit those orders.
In October 2010, the United States government issued final Screening Framework Guidance for Providers of Synthetic Double-Stranded DNA, describing how commercial providers of synthetic genes should perform gene sequence and customer screening. IDT and the other IGSC member companies supported the adoption of the Screening Framework Guidance, and IDT follows that Guidance in its application of the Harmonized Screening Protocol. For more information, please see 75 FR 62820 (Oct. 13, 2010), or https://federalregister.gov/a/2010-25728.